Superbugs in ICU: Is there any hope for solution?

Journal of Association of Physicians of India

Volumn 57, Issue 9, 2009, Pages

  Trivedi, Trupti H ^a   Sabnis, Girish R ^a  

^a LOKMANYA TILAK MUNICIPAL MEDICAL COLLEGE AND GENERAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; CROSS INFECTION; DRUG EFFECT; EDITORIAL; HUMAN; INTENSIVE CARE UNIT; MICROBIOLOGY; MULTIDRUG RESISTANCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INTENSIVE CARE UNITS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 70349491225     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (28)

1. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005; 41: 848-54.
2. Albrecht SJ, Fishman NO, Kitchen J, et al. Re-emergence of gramnegative health care-associated bloodstream infections. Arch Intern Med 2006; 166:1289-94.
3. Rice LB. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43 Suppl 2: S100-5.
4. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the Infectious Diseases Society of America. Clin Infect Dis 2006;42:657-68. (Erratum in Clin Infect Dis 2006;42:1065; comments in Clin Infect Dis 2006;43:383-4.)
5. Nicasio AM, Kuti JL, Nicolau DP. The Current State of Multidrug-Resistant Gram-Negative Bacilli in North America. Pharmacotherapy 2008;28(2):235-249.
6. Shanti M, Sekar U. Multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii infections among hospitalized patients; risk factors and outcome. J Assoc Physicians India 2009; 57:635-45.
7. Reinhart K, Meisner M, Brunkhorst F M. Markers for sepsis diagnosis: what is useful? Crit Care Clin 2006; 22: 503-19.
8. Falgas ME, Kopterides P. Risk factors for isolation of multi-drug resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 2006; 64: 7-15.
9. Trivedi TH, Shejale SB, Yeolekar ME. Nosocomial pneumonia in medical intensive care unit. J Assoc Physicians India 2000; 48:1070-73.
10. Kipnis E, Sawa T, Wiener-Kronish J. Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med Mai Infect 2006; 36:78-91.
11. Giamarellou H, Kanellakopoulou K. Current therapies for Pseudomonas aeruginosa. Crit Care Cliin 2008; 24: 261-78.
12. Manikal VM, Landman D, Saurina G, Oydna E, Lai H, Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, inter institutional spread, and relation to antibiotic usage. Clin Infect Dis 2000;31:101-6.
13. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43(Suppl 2):S49-56
14. Rahal JJ: The role of carbapenems in initial therapy for serious Gram-negative infections. Crit Care 2008, 12(Suppl 4):S5
15. Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenemcilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003;47:3442-7.
16. Turner PJ. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYST IC program. Diagn Microbiol Infect Dis 2006;56:341-4.
17. Falgas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of evidence from old and recent studies. Crit Care 2006; 10: R27.
18. Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis 2007;11:402-6.
19. Reina R, Estenssoro E, Saenz G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 2005;31: 1058-65.
20. Falagas ME, Bliziotis IA. Pandrug-resistant gram-negative bacteria: the dawn of the postantibiotic era? Int J Antimicrob Agents 2007;29:630-6.
21. Nathwani D. Tigecycline: clinical evidence and formular y positioning. Int J Antimicrob Agents 2005;25:185-92.
22. Kumar AK. MuIti Drug Resistance: Another Fatal ICU Concern. Pulmon 2006;8:84-88.
23. Gupta E, Mohanty S, Sood S, Dhawan B, Das BK and Kapil A. Emerging resistance to carbapenems in a tertiary care hospital in north India. Indian J Med Res 2006;124: 95-98
24. Kollef MH. Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit? Clin Infect Dis 2006; 43(Suppl 2):S82-8.
25. De Jonge E, Schultz M, Spanjaard L, et al. Effects of selective decontamination of the digestive tract on mor tality and acquisition of resistant bacteria in intensive care: a randomized controlled trial. Lancet 2003; 363:1011-6.
26. Veena Kumari HB, Nagarathna S and Chandramuk i A. Antimicrobial Resistance Pattern Among Aerobic Gram negative Bacilli of Lower Respiratory Tract Specimens of Intensive Care Unit Patients in a Neurocentre. Indian J Chest Dis Allied Sci 2007; 49:19-22
27. S, Kanungo R, Srinivasan S, Devi S. Emerging resistance to carbapenems in hospital acquired Pseudomonas infection: A cause for concern. Indian J Pharmacol 2006;38:287-8
28. Shorr A F. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med 2009; 37:1463-69.